Every 424B that Sunshine Biopharma Inc (SBFM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SBFM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBFM filings page.
Sunshine Biopharma Inc. (SBFM) is registering 25,477,133 shares of common stock issuable upon exercise of its outstanding Series B Warrants at a current exercise price of $1.2202 per share, implying maximum gross proceeds of $31,087,198 if all warrants are exercised for cash. The warrants expire on February 15, 2029 and their exercise price and share count are subject to anti-dilution adjustments. The company estimates net proceeds of about $31 million, to be used for general corporate purposes, including working capital. Sunshine Biopharma operates through subsidiaries Nora Pharma Inc. (60 generic prescription drugs in Canada) and Sunshine Biopharma Canada Inc. (OTC supplements), and is also developing K1.1 mRNA for liver cancer and SBFM-PL4 for SARS coronavirus infections. Risks highlighted include potential Nasdaq delisting if it cannot maintain the minimum bid price and a proposed $5 million Market Value of Listed Securities requirement, as well as significant potential dilution from 29,512,762 outstanding warrants.
Sunshine Biopharma Inc. is initiating an at-the-market common stock offering of up to $4,000,000 under a Sales Agreement with Aegis Capital Corp., acting as exclusive sales agent. Shares may be sold from time to time on Nasdaq as defined in Rule 415.
The company will pay Aegis a 3.0% cash commission on gross proceeds and reimburse specified expenses, and Aegis will be deemed an underwriter. Net proceeds are intended for general corporate purposes, including working capital. Under General Instruction I.B.6 of Form S-3, primary offerings are limited to one-third of non-affiliate market value while it remains below $75 million.
Sunshine Biopharma Inc. is offering 11,160,000 Common Units and 840,000 Pre-Funded Units in an underwritten placement with an aggregate public offering amount of $6,000,000 at a public offering price of $0.50 per Common Unit (or $0.49999 per Pre-Funded Unit) on a best efforts basis. Each Common Unit consists of one share of common stock and two Series C Warrants; each Pre-Funded Unit consists of one Pre-Funded Warrant and two Series C Warrants.
The prospectus registers the shares issuable upon exercise of the Pre-Funded Warrants and Series C Warrants. The offering contemplates net proceeds of approximately $5.0 million to the company to be used for general corporate purposes, including working capital. Shares outstanding were 5,005,945 as of May 15, 2026 and would be 17,005,945 after this offering assuming exercise of all Pre-Funded Warrants, as stated in the prospectus.